1. Introduction

Newborn genomic screening refers to the examination of a newborn child's DNA to identify genetic variations associated with inherited diseases, metabolic disorders, congenital conditions, and other medically significant abnormalities. Unlike conventional newborn screening, which generally tests for a limited number of treatable disorders through biochemical or molecular methods, genomic screening can examine a much wider range of genetic information.

In Morocco, newborn genomic screening pilot projects raise important legal questions concerning:

Protection of newborns' genetic and medical information.

Parental consent and representation of children.

Prevention of genetic discrimination.

Confidentiality of genomic databases.

Regulation of genetic testing laboratories.

Clinical validity and reliability of screening results.

Cross-border transfer of genetic information.

Government supervision of public-health research.

The child's right to privacy and future autonomy.

The central legal challenge is balancing the potential public-health benefits of early genetic diagnosis against the risks of unnecessary testing, privacy violations, uncertain findings, and misuse of children's genetic information.

Important legal qualification: Morocco's general health, biomedical research, personal-data, and bioethics-related rules provide relevant legal foundations. However, a comprehensive, dedicated statutory framework specifically governing newborn whole-genome screening pilot projects should not be assumed to exist. The distinction between existing legislation and proposed regulatory safeguards is essential.

2. Legal and Regulatory Framework in Morocco

Several Moroccan legal instruments are relevant to newborn genomic screening.

A. Constitution of Morocco, 2011

The Moroccan Constitution establishes important protections for individual dignity, equality, privacy, and access to healthcare.

Relevant constitutional principles include:

Article 24 – Privacy: Protects private life and provides an important foundation for safeguarding children's genetic information.

Article 31 – Access to healthcare: Establishes the state's responsibility to facilitate access to healthcare and medical treatment.

Article 22 – Physical and moral integrity: Provides a constitutional foundation for protecting individuals against violations of physical and psychological integrity.

Article 34 – Protection of vulnerable groups: Supports public policies directed towards protecting vulnerable persons, including children.

These principles are relevant when the government authorizes genomic screening programmes in public hospitals.

A screening project should not expose newborns to unnecessary medical interventions or collect excessive genetic information without a legitimate healthcare justification.

B. Law No. 09-08 on the Protection of Personal Data

Law No. 09-08, concerning the protection of individuals with regard to the processing of personal data, is particularly important.

It regulates the processing of personal information and establishes safeguards for sensitive information, including health-related data.

Newborn genomic screening projects may collect:

DNA sequences.

Genetic mutations.

Family medical histories.

Inherited disease indicators.

Clinical records.

Parental genetic information.

Such information requires heightened protection because genetic data can reveal information about both the child and biological relatives.

The National Commission for the Control of Personal Data Protection (CNDP) plays an important supervisory role.

A genomic screening pilot should therefore address the applicable requirements concerning lawful processing, purpose limitation, data security, retention, and international transfers.

C. Law No. 131-13 on the Practice of Medicine

Law No. 131-13 regulates the practice of medicine in Morocco.

Its relevance includes:

Professional qualifications of medical practitioners.

Medical responsibility.

Professional ethics.

Clinical decision-making.

Medical confidentiality.

Responsibility for negligent medical practices.

Genomic screening should be conducted under appropriate medical supervision. A laboratory result should not automatically be treated as a definitive diagnosis without suitable clinical interpretation.

D. Law No. 65-00 on Basic Medical Coverage

Law No. 65-00 establishes the basic medical coverage framework.

It is relevant to questions concerning the financing and accessibility of medically necessary diagnostic services.

If genomic screening becomes part of a national newborn healthcare programme, policymakers must consider whether testing and follow-up treatment are accessible to children from different socioeconomic backgrounds.

E. International Children's Rights Framework

Morocco is a party to the United Nations Convention on the Rights of the Child.

Important provisions include:

Article 3: Best interests of the child.

Article 12: Right of the child to express views, according to age and maturity.

Article 16: Protection against arbitrary interference with privacy.

Article 24: Right to the highest attainable standard of health.

These provisions are particularly significant because newborns cannot independently consent to genomic screening.

The best-interests principle must guide decisions concerning the collection, analysis, storage, and future use of newborn genomic information.

3. Regulation of Pilot Projects Under Law No. 28-13 on Biomedical Research

Law No. 28-13 of 2015, concerning the protection of persons participating in biomedical research, is one of the most important legal instruments for experimental newborn genomic screening programmes.

Its provisions become particularly relevant when a pilot project is designed to generate scientific evidence rather than merely provide established clinical diagnostic services.

A. Article 3 – Fundamental research principles

Biomedical research must respect:

Human life and health.

Physical and psychological integrity.

Human dignity and privacy.

Voluntary participation.

Informed and express consent.

Consequently, newborn genomic screening must have a scientifically justified objective and a clearly defined research protocol.

B. Articles 4–6 – Informed consent

These provisions establish requirements concerning informed consent, disclosure of research information, and withdrawal of consent.

For newborn participants, the legal representative must provide consent in accordance with the applicable statutory conditions.

Parents should receive understandable information about:

The purpose of genomic screening.

The diseases being investigated.

Possible false-positive and false-negative results.

Incidental genetic findings.

Potential psychological and familial consequences.

Storage and future use of DNA samples.

Withdrawal from the research project.

Consent to clinical screening should be distinguished from consent to long-term genetic-data storage and unrelated future research.

C. Article 8 – Confidentiality and privacy

Article 8 requires respect for participants' private lives and confidentiality of their personal information.

This is particularly important because genomic screening can identify genetic characteristics that may also reveal information about parents, siblings, and other biological relatives.

Pilot projects should therefore use appropriate encryption, restricted database access, pseudonymisation, and documented data-sharing arrangements.

D. Article 12 – Research involving minors

Article 12 is especially significant.

It provides that biomedical research involving minors is generally permitted where direct health benefits are expected, subject to free, informed, and express consent from the legal representative.

Research without direct therapeutic benefit may be authorised only under specified safeguards, including:

No serious foreseeable risk to the child's health.

Usefulness to persons with comparable characteristics.

Inability to conduct the research using another method.

The child's refusal or the legal representative's refusal or withdrawal of consent cannot simply be disregarded.

For newborn genomic screening, this provision creates an important distinction between screening for immediately treatable childhood diseases and broad exploratory sequencing that may reveal information about adult-onset conditions.

E. Articles 17–18 – Regional research ethics committees

These provisions establish regional committees responsible for reviewing biomedical research projects and their ethical acceptability.

Their multidisciplinary composition is intended to incorporate medical, biological, pharmaceutical, ethical, social, psychological, religious, and legal expertise.

A newborn genomic screening pilot should receive appropriate ethical review before recruitment begins.

F. Articles 22–27 – Research approval and supervision

These provisions establish requirements concerning research protocols, ethics review, and authorisation.

In particular:

Article 22 requires submission of the research dossier and protocol to the competent regional committee.

Article 23 permits scrutiny of examinations, samples, and procedures.

Article 24 identifies the healthcare institutions in which biomedical research may be conducted.

Article 25 requires a research protocol.

Article 26 addresses governmental authorisation of interventional biomedical research.

Article 27 establishes conditions for authorising biomedical research.

These requirements are important when a hospital or university proposes to introduce experimental whole-genome sequencing for newborns.

G. Articles 30 and 34 – International samples and liability

Article 30 regulates the transmission abroad of samples collected for biomedical research for analytical purposes, subject to the statutory conditions, including the absence in Morocco of a laboratory capable of performing the analysis to equivalent quality and good-practice standards.

Article 34 addresses the sponsor's responsibility for damage suffered by research participants where the required causal relationship with the research is established. It also provides for compensation.

These provisions are relevant when international biotechnology companies, foreign sequencing laboratories, or research sponsors participate in Moroccan newborn genomic screening programmes.

Ma Loi+2

4. Regulation of Genetic Data and Newborn Privacy

Genetic information is particularly sensitive because it can reveal inherited characteristics that remain relevant throughout a person's life.

Under Article 1 of Law No. 09-08, genetic and health information falls within the category of sensitive personal data.

The following requirements are particularly important.

CNDP supervision

The CNDP supervises compliance with Law No. 09-08.

Before establishing a genomic screening database, project organisers should assess the applicable prior declaration or authorisation requirements, particularly because genetic data is sensitive information.

Article 21 is particularly relevant to authorisation for processing sensitive data, including genetic information, subject to the statutory exceptions.

Articles 23 and 24 address security and professional confidentiality.

Articles 43 and 44 regulate international transfers of personal data.

For example, if a Moroccan hospital sends newborn DNA sequences to a foreign sequencing company, the project must examine whether the destination country provides adequate protection or whether an applicable statutory exception or CNDP authorisation is required.

A parent's agreement to participate in a study does not automatically eliminate these regulatory obligations.

bdj.mmsp.gov.ma+2

5. Regulation of Medical Laboratories and Professional Responsibility

Newborn genomic screening requires reliable laboratories and qualified medical professionals.

Two important legislative instruments are:

Law No. 12-01 concerning private medical biology analysis laboratories.

Law No. 131-13 concerning the practice of medicine.

The Moroccan Ministry of Health identifies these instruments among the legislation governing medical professions and laboratory activities.

sante.gov.ma+1

A pilot project should establish:

Laboratory quality assurance

Validation of sequencing technologies.

Standardised sample collection.

Prevention of sample contamination.

Verification of genetic variants.

Appropriate quality-control procedures.

Secure storage and transmission of results.

Medical responsibility

Medical practitioners should ensure that screening results are interpreted appropriately.

A genetic variant of uncertain significance should not automatically be treated as a confirmed disease.

Where a positive result is obtained, the child should have access to appropriate confirmatory testing and clinical evaluation.

6. Parental Consent and the Best Interests of the Newborn

Consent is one of the most difficult legal issues in newborn genomic screening.

A newborn cannot understand the consequences of genomic sequencing or independently authorise the collection and storage of genetic information.

Therefore, parental or legal-representative consent is essential where required by the applicable legal framework.

However, parental authority is not unlimited.

The following safeguards should guide the process:

First: Medical necessity

Testing should prioritise conditions for which early diagnosis can lead to effective treatment or prevention.

Second: Limited testing

The programme should avoid collecting unrelated genetic information without a strong justification.

Third: Future autonomy

The child's future right to make personal decisions about genetic information should be considered, especially for conditions that do not require medical intervention during childhood.

Fourth: Disclosure of findings

Parents should receive appropriate genetic counselling before and after testing.

Fifth: No discrimination

Genetic information should not be used to discriminate against children in education, insurance, employment, or other areas.

Sixth: Continued healthcare

A parent's refusal to participate in an experimental screening programme should not result in denial of ordinary healthcare.

7. Important International Case Laws Relevant to Morocco

There is an important distinction between Moroccan judicial precedents and international comparative decisions.

The following judgments are relevant to the interpretation of genetic privacy, children's medical rights, informed consent, and proportionality. They are persuasive comparative authorities, not binding judgments of Moroccan courts.

Case 1: S. and Marper v. United Kingdom (2008)

European Court of Human Rights · Grand Chamber · Applications Nos. 30562/04 and 30566/04 · 4 December 2008

Facts:

The case concerned the retention of fingerprints, cellular samples, and DNA profiles by police authorities after criminal proceedings had ended.

One applicant was a child who had been arrested at the age of eleven.

Legal issue:

Whether indefinite retention of biological samples and DNA profiles violated the right to privacy under Article 8 of the European Convention on Human Rights.

Judgment:

The Court found a violation of Article 8.

It recognised that biological samples and DNA profiles contain highly sensitive personal information, including information concerning health and genetic relationships.

It also emphasised the particular vulnerability of children.

Relevance to Morocco:

This judgment is important for newborn genomic screening databases.

Moroccan pilot projects should establish:

Clear retention periods.

Restrictions on secondary use.

Appropriate deletion procedures.

Protection against unauthorised disclosure.

Special safeguards for children's genetic information.

The judgment supports the principle that scientific and public-interest benefits do not automatically justify unlimited retention of genetic material.

hudoc.echr.coe.int

Case 2: Glass v. United Kingdom (2004)

European Court of Human Rights · Application No. 61827/00 · 9 March 2004

Facts:

The case involved medical treatment administered to a severely disabled child despite the objections of his mother, who acted as his legal representative.

Legal issue:

Whether the medical intervention, undertaken against parental objections, interfered with the child's rights under Article 8.

Judgment:

The Court found a violation of Article 8.

It considered that imposing medical treatment against the mother's objections interfered with the child's right to respect for private life and physical integrity.

The judgment also discussed the importance of parental involvement and judicial intervention when serious disagreements arise.

Relevance to Morocco:

This case provides guidance on parental participation in newborn genomic screening.

For example, if doctors recommend an experimental genomic test and parents refuse, the medical team should distinguish between:

Medically necessary treatment.

Established diagnostic testing.

Experimental screening.

Non-therapeutic scientific research.

Experimental research should not be imposed merely because doctors believe it may produce useful scientific information.

Bailii

Case 3: Evans v. United Kingdom (2007)

European Court of Human Rights · Grand Chamber · Application No. 6339/05 · 10 April 2007

Facts:

The case concerned stored embryos created through assisted reproduction and disagreement over their continued use.

Legal issue:

The Court examined reproductive autonomy, consent, and the rights of individuals concerning stored biological material.

Judgment:

The Court did not find a violation of Article 8 or Article 14 in the particular circumstances.

Relevance to Morocco:

Although the case concerned embryos rather than newborn genomic screening, it offers comparative guidance on the importance of consent and control over stored biological material.

Its reasoning can inform discussions about:

Storage of newborn DNA samples.

Future research use.

Withdrawal of consent.

Control over biological materials.

Balancing competing family interests.

It does not establish a direct legal rule for newborn DNA ownership in Morocco.

Case 4: Pretty v. United Kingdom (2002)

European Court of Human Rights · Application No. 2346/02 · 29 April 2002

Facts:

The case concerned the relationship between personal autonomy, bodily integrity, and state regulation in the context of an individual's request for assistance in ending her life.

Legal issue:

The Court considered the scope of privacy and autonomy protections under Article 8.

Judgment:

The Court did not find a violation of Article 8 in the particular circumstances.

Relevance to Morocco:

The judgment is useful as a comparative reference when considering personal autonomy and bodily integrity.

In newborn genomic screening, however, autonomy must be exercised through legally appropriate representation and the child's best interests, with due regard to future autonomy.

These cases provide comparative human-rights principles rather than direct rulings on Moroccan genomic screening legislation.

8. Additional Legal Issues in Newborn Genomic Screening Pilot Projects

A. Screening for Adult-Onset Genetic Diseases

One controversial issue is whether newborns should be tested for diseases that may not develop until adulthood.

For example, genomic sequencing may identify inherited predispositions to:

Certain hereditary cancers.

Adult-onset neurological disorders.

Cardiovascular conditions.

Late-onset metabolic disorders.

The legal and ethical concern is that the newborn cannot decide whether to know this information.

A suitable regulatory approach is to prioritise conditions that provide a meaningful medical benefit during childhood and defer disclosure of unrelated adult-onset findings unless there is a compelling medical justification.

B. Incidental and Uncertain Findings

Whole-genome sequencing may identify genetic variations unrelated to the original screening purpose.

Three categories should be distinguished:

Primary findings: Variants directly related to the diseases targeted by the screening programme.

Secondary findings: Other medically significant variants discovered incidentally.

Variants of uncertain significance: Genetic changes whose clinical implications are not sufficiently established.

The programme should establish clear rules on whether these findings will be reported, who will interpret them, and how families will receive counselling.

C. Genetic Discrimination

Genomic information may reveal inherited disease risks or biological relationships.

Potential misuse includes:

Discrimination by insurance providers.

Unfair treatment in educational institutions.

Stigmatisation of children with genetic disorders.

Unauthorised commercial use of genetic information.

Discrimination against particular families or communities.

Moroccan pilot projects should prohibit access to identifiable genomic information by unauthorised third parties and establish effective complaint and enforcement mechanisms.

D. Genetic Database Ownership and Control

A further issue concerns the legal status of stored biological samples and genomic datasets.

A pilot programme may involve hospitals, universities, government agencies, biotechnology companies, and foreign research institutions.

Contracts should specify:

Who is responsible for the database.

Who controls access.

Whether samples may be reused.

Whether commercial research is permitted.

When samples must be destroyed.

How participants can exercise applicable data-protection rights.

What happens when a research project terminates.

Importantly, possession of a physical sample does not automatically give a researcher unrestricted authority to use the genetic information for unrelated purposes.

E. Cross-Border Genomic Research

Moroccan newborn screening projects may require foreign sequencing facilities or international scientific collaboration.

For instance, a Moroccan university might collect newborn samples while a foreign laboratory performs advanced sequencing.

Such arrangements raise questions under:

Article 30 of Law No. 28-13 concerning transmission abroad of research samples.

Articles 43–44 of Law No. 09-08 concerning international personal-data transfers.

Applicable confidentiality and research-consent requirements.

The transfer of a DNA sample and the transfer of digital genomic information are legally distinct operations. Both must be assessed under the applicable rules.

9. Proposed Regulatory Model for Morocco's Newborn Genomic Screening Pilot Projects

Morocco could establish a dedicated regulatory framework for pilot projects through the following mechanisms.

A. Pilot-project risk classification

Moroccan regulators could distinguish three categories:

Category I – Clinical screening: Testing for established, treatable childhood conditions.

Category II – Expanded genomic screening: Testing for additional medically actionable genetic conditions.

Category III – Exploratory genomic research: Broad sequencing intended primarily to generate scientific knowledge.

Category III should receive particularly rigorous ethical review because its benefits to the individual newborn may be uncertain.

B. Independent monitoring

A pilot programme should have an independent monitoring mechanism involving:

Paediatric specialists.

Clinical geneticists.

Molecular biologists.

Data-protection specialists.

Bioethicists.

Legal professionals.

Representatives of child-health organisations.

C. Protection of economically disadvantaged families

The government should ensure that genomic screening does not become a service available only to wealthy families.

Where a pilot is publicly funded, access criteria should be transparent and based on legitimate medical and public-health considerations.

D. Transparency and public reporting

Every pilot project should publish anonymised information concerning:

Number of newborns screened.

Number of confirmed diagnoses.

False-positive rates.

False-negative rates.

Clinical outcomes.

Data breaches.

Withdrawal of consent.

Financial costs.

Long-term follow-up.

This would improve public accountability and help determine whether a pilot programme should be expanded nationally.

10. Legal Liability for Violations in Newborn Genomic Screening

Different participants may incur different forms of legal responsibility.

Examples of potentially actionable failures include:

Incorrectly identifying a healthy newborn as having a serious genetic disease.

Failing to confirm a positive screening result.

Disclosing genetic information without lawful authority.

Retaining samples beyond justified periods.

Conducting research without the required approvals.

Transferring samples or genetic data contrary to applicable legislation.

Failing to provide appropriate medical follow-up.

The legal consequences depend on the applicable statutory provision, the nature of the wrongdoing, and proof of the relevant elements of liability.

11. Challenges in Implementing Newborn Genomic Screening in Morocco

Several obstacles may affect the development of these programmes.

1. Absence of a dedicated genomic-screening statute

General health and research laws provide important safeguards, but specific rules for newborn whole-genome sequencing, incidental findings, and long-term genomic databases require further development.

2. Limited specialist infrastructure

Advanced genomic screening requires trained geneticists, molecular laboratories, genetic counsellors, and reliable clinical interpretation systems.

3. Inadequate public awareness

Parents may not fully understand the difference between conventional newborn screening and whole-genome sequencing.

4. Uncertainty about long-term findings

Some genetic variations may have unknown clinical significance. Premature disclosure can create unnecessary anxiety.

5. International data governance

Foreign laboratories and international research institutions may create difficulties concerning sample transfers, data security, jurisdiction, and accountability.

6. Long-term financial sustainability

Genomic screening is not simply a laboratory exercise. It requires confirmatory testing, treatment, counselling, and long-term medical follow-up.

12. Recommendations for Legal Reform

Morocco could strengthen its regulatory system through the following reforms:

Introduce dedicated regulations governing newborn genomic screening.

Establish a national genomic-screening oversight committee.

Create standardised parental consent documents.

Introduce specific rules for incidental and adult-onset genetic findings.

Establish a national framework for the retention and destruction of newborn DNA samples.

Strengthen CNDP supervision of genomic databases.

Require independent validation of genomic screening technologies.

Establish clear rules for international genomic-data transfers.

Introduce stronger protections against genetic discrimination.

Establish long-term clinical follow-up and compensation mechanisms.

13. Conclusion

The regulation of newborn genomic screening pilot projects in Morocco involves an intersection of constitutional rights, medical law, biomedical research legislation, personal-data protection, and international children's rights.

Law No. 09-08 provides important protection for genetic and health information, while Law No. 28-13 establishes safeguards for individuals participating in biomedical research, including minors. Laws No. 12-01 and No. 131-13 provide additional foundations for regulating medical laboratories and medical professionals.

The decisions in S. and Marper v. United Kingdom and Glass v. United Kingdom provide useful comparative judicial guidance concerning genetic privacy, children's physical integrity, and parental participation in medical decisions.

Ultimately, Morocco's regulatory approach should ensure that newborn genomic screening serves legitimate medical purposes, protects children's privacy, respects parental consent, and does not compromise the child's future autonomy.

The most important principle is that a newborn's genetic information should be collected and used primarily to protect that child's health, not to create an unrestricted lifelong genetic record.

14. Important Legal References and Authorities

Useful official and legal research sources:

Moroccan Law No. 09-08 – Official legal text.

CNDP – Moroccan data-protection legislation.

Moroccan Law No. 28-13 – Biomedical research provisions.

Moroccan Ministry of Health – Medical laboratory legislation.

S. and Marper v. United Kingdom – ECHR judgment.

Glass v. United Kingdom – ECHR judgment.

Case-law qualification: The cases discussed above are comparative international precedents. I have not identified a reported Moroccan court judgment specifically deciding the legality of newborn whole-genome screening or a newborn genomic screening pilot project. It would therefore be inaccurate to present these international decisions as established Moroccan precedents.